Recursion Pharmaceuticals (NASDAQ:RXRX) Stock Price Down 4.6% - What's Next?

Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX - Get Free Report)'s share price fell 4.6% during mid-day trading on Friday . The company traded as low as $7.05 and last traded at $7.31. 6,023,760 shares changed hands during trading, a decline of 12% from the average session volume of 6,855,345 shares. The stock had previously closed at $7.66.

Analyst Upgrades and Downgrades

RXRX has been the topic of a number of recent analyst reports. Leerink Partners reduced their price target on shares of Recursion Pharmaceuticals from $9.00 to $8.00 and set a "market perform" rating on the stock in a research report on Tuesday, September 3rd. Jefferies Financial Group reduced their target price on Recursion Pharmaceuticals from $8.00 to $6.00 and set a "hold" rating on the stock in a report on Tuesday, September 3rd. Finally, Needham & Company LLC reaffirmed a "buy" rating and set a $11.00 price target on shares of Recursion Pharmaceuticals in a report on Wednesday, December 11th. Three analysts have rated the stock with a hold rating and two have issued a buy rating to the stock. According to MarketBeat.com, Recursion Pharmaceuticals currently has an average rating of "Hold" and an average target price of $9.25.

Recursion Pharmaceuticals Stock Performance

The stock's 50 day simple moving average is $6.81 and its two-hundred day simple moving average is $7.15. The company has a market capitalization of $2.12 billion, a P/E ratio of -4.83 and a beta of 0.85. The company has a debt-to-equity ratio of 0.04, a current ratio of 4.35 and a quick ratio of 4.35.

Recursion Pharmaceuticals (NASDAQ:RXRX - Get Free Report) last posted its quarterly earnings data on Wednesday, November 6th. The company reported ($0.34) earnings per share for the quarter, missing the consensus estimate of ($0.33) by ($0.01). The company had revenue of $26.08 million during the quarter, compared to the consensus estimate of $12.62 million. Recursion Pharmaceuticals had a negative return on equity of 76.56% and a negative net margin of 579.52%. The business's revenue for the quarter was up 147.6% on a year-over-year basis. During the same quarter last year, the firm earned ($0.43) EPS. As a group, research analysts expect that Recursion Pharmaceuticals, Inc. will post -1.57 earnings per share for the current year.

Insider Activity at Recursion Pharmaceuticals

In other news, CFO Michael Secora sold 15,000 shares of the firm's stock in a transaction on Wednesday, November 13th. The stock was sold at an average price of $7.66, for a total value of $114,900.00. Following the transaction, the chief financial officer now directly owns 1,499,631 shares in the company, valued at $11,487,173.46. This trade represents a 0.99 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, Director Blake Borgeson sold 11,447 shares of Recursion Pharmaceuticals stock in a transaction on Tuesday, October 1st. The stock was sold at an average price of $6.22, for a total value of $71,200.34. Following the sale, the director now directly owns 7,098,428 shares of the company's stock, valued at approximately $44,152,222.16. This trade represents a 0.16 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 101,788 shares of company stock worth $682,691 over the last 90 days. Insiders own 15.75% of the company's stock.

Institutional Investors Weigh In On Recursion Pharmaceuticals

Large investors have recently bought and sold shares of the company. Allspring Global Investments Holdings LLC acquired a new position in shares of Recursion Pharmaceuticals in the 3rd quarter valued at $25,000. Farther Finance Advisors LLC increased its holdings in shares of Recursion Pharmaceuticals by 176.9% in the third quarter. Farther Finance Advisors LLC now owns 6,404 shares of the company's stock worth $42,000 after acquiring an additional 4,091 shares in the last quarter. Amalgamated Bank grew its position in shares of Recursion Pharmaceuticals by 52.4% in the 2nd quarter. Amalgamated Bank now owns 7,152 shares of the company's stock valued at $54,000 after purchasing an additional 2,459 shares during the period. KBC Group NV increased its stake in Recursion Pharmaceuticals by 79.9% during the 3rd quarter. KBC Group NV now owns 7,602 shares of the company's stock worth $50,000 after purchasing an additional 3,377 shares in the last quarter. Finally, San Luis Wealth Advisors LLC acquired a new stake in Recursion Pharmaceuticals during the 3rd quarter worth approximately $69,000. Institutional investors own 89.06% of the company's stock.

Recursion Pharmaceuticals Company Profile

Recursion Pharmaceuticals, Inc operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 2 clinical trial to treat AXIN1 or APC mutant cancers.